LungCancer

J&J's Groundbreaking Lung Cancer Treatment Outshines AstraZeneca's Tagrisso

3 months ago

In a significant development for lung cancer treatment, Johnson & Johnson has announced promising results from its clinical trials, demonstrating that its new combination therapy substantially enhances survival rates compared to AstraZeneca's widely used medication, Tagrisso. This discovery has created a fresh wave of optimism among medical professionals and patients alike, as the competition to revolutionize lung cancer treatment intensifies.

AstraZeneca and Daiichi Sankyo Withdraw EU Application for Lung Cancer Treatment

3 months ago

In a significant development within the pharmaceutical industry, AstraZeneca and its partner Daiichi Sankyo have decided to withdraw their application for the marketing authorization of a lung cancer treatment in the European Union. This decision comes as a blow to both companies, particularly after they had invested substantial resources into the drug's development and regulatory approval.

AstraZeneca's Tagrisso Secures EU Approval for New Lung Cancer Application

3 months ago

AstraZeneca has announced a significant breakthrough in its oncology portfolio as its lung cancer medication, Tagrisso, has received approval from the European Union for an additional indication. This landmark decision allows Tagrisso, which is primarily used to treat non-small cell lung cancer (NSCLC), to be administered for patients with early-stage lung cancer who are at a higher risk of disease recurrence following surgery.